SRI 31215 TFA NEW
| Price | $36 | $88 | $137 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-17 |
Product Details
| Product Name: SRI 31215 TFA | CAS No.: 1832686-44-8 |
| Purity: 99.97% | Supply Ability: 10g |
| Release date: 2024/11/17 |
Product Introduction
Bioactivity
| 名稱 | SRI 31215 TFA |
| 描述 | SRI 31215 TFA, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation with IC50s of 0.69 μM, 0.65 μM, 0.3 μM, |
| 細(xì)胞實(shí)驗(yàn) | DU145 cells were cultured in 6-well tissue culture plates at a density of 1 103 cells per well.?After colonies formed (6-8 days), cells were serum-starved overnight and were then treated with recombinant HGF (10 ng/ml) or with conditioned media from 18Co fibroblasts in the presence or absence of SRI 31215 (10 μM) or the MET kinase inhibitor JNJ 38877605 (1 μM) for 24 hours.?Cells were washed with PBS and colonies were fixed and stained with 0.5% crystal violet solution in 6% glutaraldehyde. |
| 體外活性 | SRI 31215 inhibits fibroblast-induced MET activation, epithelial-mesenchymal transition and migration of cancer cells.?SRI 31215 overcomes primary resistance to cetuximab and gefitinib in HGF-producing colon cancer cells and prevents fibroblast-mediated resistance to EGFR inhibitors.?Thus, SRI 31215 blocks signaling between cancer cells and fibroblasts and inhibits the tumor-promoting activity of cancer-associated fibroblasts. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 25 mg/mL (38.6 mM) |
| 關(guān)鍵字 | c-Met/HGFR | SRI 31215 TFA | SRI-31215 | inhibit | SRI31215 | Inhibitor |
| 相關(guān)產(chǎn)品 | Cabozantinib | Capmatinib 2HCl | SGI-7079 | (±)-Norcantharidin | L-Ascorbic acid 2-phosphate trisodium | Crizotinib | Amuvatinib | Norcantharidin | Cabozantinib S-malate | Capmatinib xHCl | Bacitracin Zinc | Capmatinib |
| 相關(guān)庫(kù) | 抗結(jié)直腸癌化合物庫(kù) | 神經(jīng)再生化合物庫(kù) | 經(jīng)典已知活性庫(kù) | 膜蛋白靶向化合物庫(kù) | 酪氨酸激酶分子庫(kù) | 激酶抑制劑庫(kù) | 抑制劑庫(kù) | NO PAINS 化合物庫(kù) | 已知活性化合物庫(kù) | 抗肝癌化合物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $52.00/2mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $0.00/1kg |
VIP2Y
|
Sichuan HongRi Pharma-Tech Co.,Ltd
|
2024-01-18 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY